






































Inflammatory Bowel Diseases Elevate the Risk of Developing
Acute Pancreatitis
A Meta-analysis
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Objectives: Increasing data suggest that acute pancreatitis (AP) occurs
more frequently among patients with inflammatory bowel diseases (IBDs)
than in the non-IBD population; however, currently no comprehensive
meta-analysis is available.
Methods: Systematic literature search was conducted in 4major databases.
We included observational studies sampling from the general population.
Basic study characteristics and crude incidences of AP were extracted.
Pooled odds ratios (ORs) with 95% confidence interval (CIs) were calcu-
lated using the random-effects model. Subgroupswere set up by Crohn dis-
ease and ulcerative colitis. Heterogeneity was tested with I2 statistics.
Results: Eight studies were eligible for the analysis. The odds of AP were
3 times higher in IBD (OR, 3.11; 95% CI, 2.93–3.30; I2, 0.0%), signifi-
cantly higher in Crohn disease than in ulcerative colitis (P < 0.001; OR,
4.12 vs OR, 2.61; I2, 0.0%). The pooled annual incidence of AP in IBD
was 210/100,000 person-years (95% CI, 84–392/100,000 person-years;
I2, 98.66%).
Conclusions: We confirmed that IBD elevates the risk of AP and of
100,000 IBD patients 210 AP cases are to be expected annually. Therefore,
it is important to include pancreatic enzyme level measurements and ra-
diological investigations in the workup of IBD patients with acute ab-
dominal pain.
KeyWords: inflammatory bowel disease, acute pancreatitis, meta-analysis,
epidemiology, extraintestinal manifestation, pancreatic involvement
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I nflammatory bowel disease (IBD) is a chronic inflammatorycondition of the gastrointestinal (GI) tract that comprises Crohn
disease (CD) and ulcerative colitis (UC). The number of affected
patients has been growing in recent decades both in adults and
children creating an increasing burden on GI units.1 Inflammatory
bowel disease has a multifactorial etiology where genetic predis-
position, environmental factors, and altered intestinal microflora
could lead to the intestinal immune abnormalities that fuel the mu-
cosal inflammation.2 Although the main symptoms are connected
to the GI tract, IBD is a systemic disease that often presents with
associated conditions or extraintestinal manifestations (EIM): der-
matologic, musculoskeletal, oral, ocular, cardiovascular, neuro-
logic, hepatobiliary, or pancreatic lesions.3,4
The most common pancreatic pathologies associated with IBD
are acute pancreatitis (AP) and asymptomatic pancreas enzyme level
elevations (for a recent review, see Iida et al5). Acute pancreatitis is a
sterile inflammatory condition of the pancreatic tissue characterized
by the activation of pancreatic enzymes inside the pancreas for vari-
ous reasons; the most common etiologies in the general population
are biliary obstruction and excessive ethanol consumption.6,7 Al-
though these non–IBD-specific etiologies can be observed in IBD
patients as well, several publications suggest that IBD is associ-
ated with an elevated risk for AP.8–10 Based on case reports and
cohort studies, 2 disease-specific forms of AP can be seen in IBD:
one is most likely related to the pathogenesis of IBD and, therefore,
can be considered as EIM of IBD, whereas the other form is a conse-
quence of the management of IBD or its associated diseases (eg,
biliary stones).4 However, the distribution of these etiologies in
IBD associated AP is yet to be explored. Likewise, to our knowl-
edge, no comprehensive synthesis of the large-scale studies
reporting the odds or the annual incidence of AP in IBD is avail-
able. Therefore, we aimed to explore, analyze, and systematically
assess the current literature to provide evidence-based data on the
association of AP and IBD.
MATERIALS AND METHODS
This study was reported according to the Preferred Reporting
Items for Systematic review andMeta-Analysis (PRISMA) guide-
lines.11 The review protocol was registered on the PROSPERO
International Prospective Register of Systematic Reviews
(CRD42017080464).
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Search Strategy
A systematic search was conducted in 4 major electronic da-
tabases (MEDLINE via PubMed, Embase,Web of Science, Scopus)
up to June 19, 2019 (date of the last search), without any search
restrictions. The search strategy used comprehensive strings of
words with variations of the terms “pancreatitis” in combination
with term variations for “inflammatory bowel diseases,” “Crohn's
disease,” or “ulcerative colitis.” The exact search query used for
the search can be found in Supplementary Table 1, http://links.
lww.com/MPA/A823. The reference lists of selected articles were
also checked.
Study Selection and Eligibility Criteria
Selection of the studies and screening was conducted by 2 in-
vestigators (B.T. and B.S.) independently. The screening was per-
formed through a review of the titles and abstracts of the records.
Studies that met the inclusion criteria and those with abstracts that
lacked crucial information for the decision regarding their exclu-
sion were retrieved for full-text evaluations. Decisions of eligibil-
ity and disagreements were resolved through discussion or by a
third reviewer (G.V.). To be included in this review, studies had
to meet all of the following criteria: (1) completed and published
observational studies with human subjects, (2) the use of objective
definitions of IBD andAP, (3) the provision of quantitative reports
of IBD and AP, and (4) all participants had been counted only
once in the published report. To appraise the odds of AP in IBD
the following PECO was used: (P) general population, (E) IBD
patients, (C) non-IBD population, and (O) odds of AP. Studies that
did not report the incidence of AP either in the IBD or the non-IBD
population or the reported data were redundant (ie, a participant
could be counted more than once in the final report) were excluded.
To examine the annual incidence of AP in IBD, we included studies
sampling from the IBD population (P) and reporting incidence rates
of AP (O) over an observation period given in person-years (PYs).
Studieswere not included if they reported onlymean follow-up data
or reported redundant data. Conference abstracts were excluded
from both analyses. When studies reported the same population
(database) and period, the most recent study was selected for
inclusion.
Data Extraction
The same authors conducted the data extraction indepen-
dently, and disagreements were resolved by consensus. Name of
the first author, date of publication, geographical location, study
type, study period, age-range of included individuals, the sub-
type(s) of IBD, number of IBD patients, crude incidence of AP
cases (for IBD and non-IBD population, respectively), adjusted
relative measures, and the observation period of the study in
PYs were extracted using a data extraction table, if applicable
(Table 1.).
Data Synthesis and Analysis
Odds ratios (ORs) were calculated from the crude incidences
and pooled ORs or event rates with 95% confidence intervals
(CIs) were calculated. We applied the random-effects model
with the DerSimonian-Laird estimation.18 Cochrane Q, I2,
and χ2 tests were used to quantify statistical heterogeneity
and gain probability values, respectively. Based on Cochrane
handbook, I2 = 100% (Q − df )/Q and represents the magnitude
of the heterogeneity (I2 = 30–60% –moderate; 50–90% – substan-
tial; 75–100% – considerable heterogeneity), and P < 0.1 indicated
significant heterogeneity.19 All statistical analyses were performed
using STATA 16.0 (Stata Corporation, College Station, Tex).
Risk of Bias and Quality of Evidence
Following the Cochrane Prognosis Methods Group recom-
mendation,20,21 the quality assessment of prognostic studies was
made using the Quality in Prognosis Studies (QUIPS) tool. First,
6 important domains were critically appraised to evaluate validity
and bias in the studies: (1) study participation, (2) study attrition,
(3) prognostic factor measurement, (4) outcome measurement, (5)
study confounding, and (6) statistical analysis and reporting.20
Each domain contained between 3 and 7 prompting items to be
rated on a 4- (yes/partial/no/unsure) or 2-grade scale (yes/no). In
a final stage, the overall judgment of the risk of bias (RoB) within
each domain was made based on the rated items; all of the re-
sponses to the prompting items were taken together when judging
a domain's overall RoB, which was expressed on a 3-grade scale
(high, moderate, or low RoB). Hence, the QUIPS assessment re-
sults in 6 ratings of RoB, 1 for each domain. The final RoB of
each study was decided by the number of domains with high
and low RoB: studies were considered to have low overall RoB
if none of the 6 domains had high and most of the domains had
low RoB; high overall RoB was judged when 2 or more domains
had high RoB, or less than half of the domains had low RoB; oth-
erwise, the overall RoB was judged to be moderate. To examine
small study effects, we used the visual assessment of a funnel plot
because tests for funnel plot asymmetry are not advised in analy-
ses with fewer than 10 studies.22
Ethics Approval
Ethical approval was not required as data is not individual-
ized, and primary data were not collected.
RESULTS
Search and Study Selection
The search of 4 electronic databases resulted in 9178 records
(Embase 3540, Scopus 3132, Web of Science 1198, and PubMed
1308), of which 3627 nonduplicate articles were screened by title
and abstract. One additional article was found eligible based on
reference lists of the studies screened by full text.16 The overview
of screening and study selection is shown in Figure 1. The articles
selected for full-text screening were handled together for the 2
analyses (143 articles were screened). From a total of 8 articles,
69,10,14–17 and 49,12–14 studies were included in the 2 final analy-
sis, respectively. The basic characteristics and main findings of
the 8 articles included in our study are shown in Tables 1 and 2.
Analysis of the Odds of AP in IBD
We first analyzed the odds of AP in IBD. Of the 6 eligible
studies, 1 was cross-sectional, 2 were prospective cohort, and 3
case-control studies; the (International Coding of Diseases [ICD]-
based) definition of cases was defined to be AP in all case-control
studies,10,15,16 and the control groups had been selected accordingly.
The 6 articles contained data of 1,309,278 people from Denmark,
Sweden, South Korea, and Taiwan. The pooled odds of AP in IBD
was 3 times higher (OR, 3.11; 95% CI, 2.93–3.30; I2 = 0.0%;
Fig. 2) compared with the non-IBD population.
Of the 6 studies, 3 reported incidences of AP events broken
down to CD and UC subpopulations and, therefore, were eligible
for subgroup analysis. The analysis has found that the odds of AP
in CD patients was significantly higher than that in UC patients
(OR, 4.12; 95% CI, 3.75–4.54; I2 = 0.0% vs OR, 2.61; 95% CI,
2.40–2.83; I2 = 0.0%; P < 0.0001; Fig. 3).
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Analysis of the Annual Incidence of AP in IBD
Four studies reported the incidence rates of AP among IBD
patients with the time of observation period given in PYs: 2 prospec-
tive and 2 retrospective studies. Three studies observed all IBD pa-
tients, including both CD and UC patients, whereas 1 study followed
up only UC patients. The 4 studies covered a sum of 268,859
PYs observation time. The pooled incidence rate of AP in IBD
was 0.21% (95% CI, 0.084%–0.392%), for example, 210/
100,000 PYs (95% CI, 84–392/100,000 PYs). The forest plot of
the analysis is shown in Figure 4.
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FIGURE 1. PRISMA flowchart.11
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Heterogeneity and Quality Assessment of Data
The assessment of the odds of AP in IBD proved to be homo-
geneous (I2 = 0.0%; P = 0.848), whereas high heterogeneity was
detected (I2 = 98.66%; P < 0.001) in the analysis of the annual in-
cidence of AP in IBD. In this latter case, because of the low num-
ber of studies, the source of heterogeneity could not be investigated
by any further subgroup analysis.












Reported Measures Adjusted for
Chen et al,
20169
3.24 N/A N/A 318 Hazard ratio: CD: 3.4 (95%
CI, 2.7–3.26) UC: 2.49 (95%
CI, 1.91–3.26)
Age, sex, alcohol-related disease, biliary stone,
hypertension, hyperlipidemia, diabetes mellitus,
obesity, hepatitis B and C, COPD,
hypertriglyceridemia, cardiovascular disease,
chronic kidney disease, hypercalcemia
Kim et al,
201712
N/A N/A N/A 153 N/A N/A
McAuliffe
et al, 201513
N/A N/A N/A 360 N/A N/A
Munk et al,
200410
2.90 4.28 1.77 N/A N/A N/A
Rasmussen
et al, 199914
2.73 4.33 2.09 76 Standardized incidence ratio:










2.80 N/A N/A N/A N/A N/A
Yang et al,
201817
3.11 4.12 2.64 N/A Standardized prevalence ratio:
CD: 4.94 (95% CI, 4.47–5.40)
UC: 2.48 (2.28–2-68)
Sex, age
*Crude ORs, calculated based on published data.
COPD indicates chronic obstructive pulmonary disease; N/A, no data published.
FIGURE 2. Pooled ORs of AP in IBD (vs non-IBD population).
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Risk of bias of the included articles in the 2 analyses was
assessed by 6 domains, respectively using the QUIPS tool (Sup-
plementary Table 2, http://links.lww.com/MPA/A823).
In the analysis of ORs, the overall quality of included studies
was high: RoB was low in 5 and moderate in one of the 6 articles.
Study participation, outcome (AP) measurement, and statistical
FIGURE 3. Pooled ORs of AP in CD and UC.
FIGURE 4. The pooled annual incidences of AP in IBD.
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analysis and reporting domains were judged to have low RoB in
all included studies. The study attrition domain was assessed only
in prospectively recruiting studies9,14,15 and was found to have
moderate RoB in all 3 studies. There was 1 study with moderate
RoB in the measurement of prognostic factor (IBD) domain and
2 in the Study confounding domains, respectively; all other stud-
ies had low RoB in these domains (Supplementary Table 2A,
http://links.lww.com/MPA/A823). Visual assessment of the fun-
nel plot suggested no serious small study effects.
In the analysis of the annual incidence, the overall quality of
the included articles is moderate: RoB was low in one and moder-
ate in 3 of the 4 studies. The measurement of prognostic factor
(IBD) and statistical analysis domains received low RoB judg-
ment for all studies. The study participation and the study con-
founding domains were judged to be low once and moderate
thrice. The RoB of the study attrition domain was assessed only
in the prospective studies and was found to be moderate in both
cases. The outcome (AP) measurement domain was of moderate
RoB in one study and low in the other 3 studies (Supplementary
Table 2B, http://links.lww.com/MPA/A823). Because of the type
of outcomemeasure (event rates), the presence of publication bias
could not be ruled out.
DISCUSSION
Acute pancreatitis is a potentially serious inflammatory dis-
order with a possibly high mortality rate.23,24 The leading symp-
tom of AP is acute abdominal pain. Beside others, AP can occur
in association with IBD, where the clinical symptoms of the 2 con-
dition may be difficult to differentiate. In IBD, acute abdominal
pain may occur because of a severe relapse of the disease, subileus
(as a consequence of strictures), or an intra-abdominal abscess.
The overlapping symptoms of AP and these complications may
delay the appropriate diagnostic workup such as the measurement
of serum lipase and amylase levels. Since the early management of
AP is crucially important,25,26 increased surveillance leading to an
earlier diagnosis may save patients’ lives.
In the last 50 years, an emerging number of case reports and
clinical studies suggested that AP is more frequent in IBD; how-
ever, the number of population-wide studies and therefore, firm
evidence addressing this association is limited. To our knowledge,
this current meta-analysis is the first to investigate the association
between AP and IBD. We aimed to summarize the currently avail-
able findings of large-scale studies. We have concluded that the
pooled odds for AP in IBD is 3 times higher (OR, 3.11) than in
the non-IBD population (Fig. 2), the odds are higher in CD than
in UC (Fig. 3), and the pooled annual incidence is 210/100,000
PYs (Fig. 4). The number of studies and the reported data has
proved to be insufficient for a more detailed stratification, includ-
ing analysis of etiological distribution.
Ball et al27 suggested at first an association between pancre-
atic involvement and IBD based on autopsy studies of UC patients.
In the current guidelines and reviews, AP is the most frequently
mentioned pancreatic lesion in IBD4,28–30; however, no clear rec-
ommendations for the optimal clinical diagnostic workup are
stated. This may be explained by the variety of contributing etiol-
ogies and the lack of firm evidence. Because the current hypoth-
eses on the possible background mechanisms causing this
association between AP and IBD are strongly connected to the
different etiologies of the pancreatic inflammation, and, therefore,
are hard to discuss independently, we also wanted to synthesize
the available evidence. However, we were unable to find suitable
data for the quantitative synthesis of the different etiologies of
AP in IBD. Therefore, we can only give a summary of the possible
etiologies with some reference to the possible mechanisms of the
connection between AP and IBD.
In IBD, the etiology of AP can be divided into 3 groups.4
Some AP cases share common pathogenetic pathways with IBD
and, therefore, could be considered as EIMs of IBD: these are
the cases of autoimmune, granulomatous, idiopathic, and primary
sclerotizing cholangitis associated pancreatitis (provided that they
occur in association with IBD). Another major group of AP cases
associated with IBD is related to the medical treatment of the
disease: drug-induced (especially thiopurine-induced), post-endoscopic
retrograde cholangiopancreatography (ERCP), postenteroscopy
pancreatitis, and AP secondary to duodenal CD are in this group.4
Besides the previously mentioned causes, the group of “classical”
etiologies (eg, biliary obstruction, ethanol abuse) also occurs; how-
ever, there is major controversy on the proportion of these 3
groups of etiologies in the published studies.
One of the possible candidates that are presumed to be caus-
ing the elevated number of AP cases in IBD is biliary obstruction.5
In the general population, cholelithiasis can be responsible for up
to 40% of the cases31 and several studies show an elevated risk for
cholelithiasis in IBD.32–34 However, studies focusing on AP in
IBD were so far unable to undoubtedly confirm biliary pancreati-
tis as a major factor behind the elevated chance of AP in IBD.
Moolsintong et al35 retrospectively analyzed the clinical features
and outcomes of 48 CD patients with AP in the United States
between 1976 and 2001 and found that biliary and idiopathic
AP were equally frequent, each corresponding for 21% of cases,
followed by alcohol abuse (15%), duodenal CD (15%),
thiopurine-induced AP (13%), and post-ERCP pancreatitis (10%).
Later, in a large Spanish cohort, Bermejo et al8 found that the most
of AP cases were attributed to drug exposure (64%), whereas 20%
were idiopathic, 12% biliary, and 4% ofmiscellaneous etiology (du-
odenal CD, post-ERCP, hypertriglyceridemia, etc). Another team
analyzed all the hospital admissions during 2005 and 2011 with a
primary diagnosis of AP and a co-diagnosis of IBD in the United
States, but they focused only on alcohol and drug abuse, and biliary
etiologies.36 They have shown that alcohol abuse was also recorded
in approximately 12% of cases (11.6% in CD and 12.1% in UC)
and 21% of controls. The rate of cases attributable to medications
was found to be significantly higher in CD (6.8% vs 4.9%) but
not in UC, and they observed the diagnosis of biliary obstruction
less frequently in IBD compared with controls (2.4% vs 4.4%),
both in CD and UC. The latest study addressing the etiology of
AP in UC from a single referral center in South Korea has shown
that 45% of patients had drug induced (of which 55% thiopurine),
25% had autoimmune, 18% idiopathic, and 12% gall stone–
induced pancreatitis, but they have not evaluated alcohol abuse.12
In summary, it seems that “classical” risk factors including
biliary obstruction, similarly to the general population, have an
important role in IBD, but the proportion of the reported etiologies
in different studies vary highly. Another important candidate
behind the elevated chance of AP in IBD is medical treatment-
associated pancreatitis. Accordingly, most of the studies uni-
formly document a significant proportion (up to 65%) of
drug-induced pancreatitis, especially thiopurine-induced cases.
Although thiopurine-induced pancreatitis (TIP) is usually
considered as a mild complication of IBD because the clinical
course of the most cases is mild,37 patient with TIP might require
the discontinuation of the ongoing thiopurine therapy and a choice
of a more complex treatment.38 Thiopurine-induced pancreatitis
usually occurs within the first 30 days after the start of treatment,
in 1.5% to 7% of treated patients.8,12,37,39,40 Bermejo et al8 reported
that 56% of AP cases in their IBD cohort were related to thiopurine
exposure and most cases was seen in CD (65% vs 22% of all AP
cases in CD and UC, respectively). In a recent study, pediatric
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IBD patients during azathioprine treatment had an almost 6 times
higher chance for AP compared with no treatment with azathio-
prine (ratio of incidence rates, 5.82; 95% CI, 2.46–13.72); inci-
dence rate of AP was 49.1 event per 1000 PYs during treatment.39
Another interesting finding is that azathioprine-induced pancrea-
titis was found more frequently in CD (4.9%) compared with
other conditions treated with azathioprine (autoimmune hepatitis
(1.5%), renal transplantation (0.5%), and liver transplantation
(0.4%) and 0% in UC, rheumatoid arthritis, systemic lupus
berythematosus, orWegener granulomatosis,P < 0.05).41 Although
the sex distribution of all AP cases in IBDwas found shifted toward
males in population-based studies,9,14 a slight female dominance
was observed in several reports of TIP in IBD.42–46
In our analysis, we originally aimed to determine the propor-
tion of the certain etiologies of AP associated with IBD; however,
we did not reach this goal because of the low number of eligible
studies and lack of published data on etiologies in the eligible
ones. Furthermore, although we were able to confirm the associa-
tion betweenAP and IBD, the causative relationship of the 2 could
not be stated. Until we gather firm evidence either on the distribu-
tion of etiologies or on the causative connection between IBD and
AP, this remains only an interesting association clinicians should
be aware of. Therefore, to provide firm evidence, further large-scale
studies dedicated to exploring the etiological distribution and the
clinical course of AP in IBD are highly needed.
There are several strengths and limitations of this study, and
therefore, the results of this meta-analysis should be treated with
caution. The main strength of our study is the robust size of the
pooled population and the use of the PRISMA guidelines. An-
other strength is that in our analysis, no heterogeneity was ob-
served when pooling the ORs of AP in IBD (I2 = 0%).
There are also limitations to our study. One is the low number
of eligible articles included, which consequently led to a limited
number of analyses. Another major limitation is that the ORs re-
ported in this meta-analysis are calculated based on the reported
number of events in the investigated publications, and therefore,
are crude ORs. Adjusted ORs for major risk factors of AP could
not be calculated because of the lack of information. Pooled anal-
ysis of adjusted outcome measures was also not available because
they were only reported for IBD in general in 1 study and both
for CD and UC in 3 studies, and all studies used different out-
come measures.
Because IBD is a heterogeneous disease, treating it as one
homogeneous patient group, as our main analysis did, could lead
to oversimplified and indirect results. However, we were able to
conduct a subgroup analysis of 4 studies based on the IBD sub-
types and, therefore, provide a clinically more relevant outcome.
Unfortunately, none of the eligible studies addressed the occur-
rence of AP based on anatomic location or clinical behavior of
IBD, which would allow further subgroup analyses and help de-
scribe the topic more precisely. Similarly, no comparison analysis
could bemade based on the etiology or behavior of AP, which also
simplifies an otherwise complex outcome. In the analysis of an-
nual incidence significant heterogeneity was seen (I2 = 98.67%),
however, in prognostic studies with large sample sizes, a high het-
erogeneity could be observed frequently.21 Another reason for the
high heterogeneity observed in this analysis might be the different
geographical and temporal distribution of the studies: the studies
originated from Taiwan,9 South Korea,12 the United States,13 and
Denmark14; the Danish study was conducted in the 1990s, whereas
the 3 others in the late 2010s.
In conclusion, in this first meta-analysis on the topic, we
showed that the odds of AP in IBD is 3 times higher than that in
the non-IBD population. Current clinical guidelines only mention
AP as a possible EIM of IBD4 but lack the recommendations for
an optimal diagnostic workup to rule out AP in patients with ab-
dominal complaints. Based on this meta-analysis, approximately
21 AP case per 10,000 IBD patient can be anticipated annually,
which emphasize the importance of pancreatic enzyme measure-
ments and pancreatic imaging examinations in symptomatic IBD
patients. Because CD patients have significantly higher odds of
AP than patients with UC, more thorough surveillance of pancre-
atic involvement in CD is advisable. Unfortunately, the etiology
and clinical course of AP in IBD remain a topic, where further
large-scale studies are needed.
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